<DOC>
	<DOCNO>NCT00091949</DOCNO>
	<brief_summary>The purpose study determine pioglitazone effective preventing future stroke heart attack among non-diabetic person recent ischemic stroke .</brief_summary>
	<brief_title>Insulin Resistance Intervention After Stroke Trial</brief_title>
	<detailed_description>Among patient throughout world experience transient ischemic attack ( TIA ) ischemic stroke , subsequent stroke heart attack major cause death disability . Within 4 year initial TIA ischemic stroke , 16 percent patient recurrent stroke 9 percent heart attack . Prevention vascular event , therefore , critically important health patient stroke . The IRIS trial test new treatment strategy base evidence link insulin resistance increase risk stroke vascular disease . Insulin resistance condition insulin , normal human hormone , work effectively body resistant effect . This condition lead diabetes think cause blood vessel disease , include stroke heart attack , patient without diabetes . Insulin resistance affect 50 % stroke patient effectively modify thiazolidinedione ( TZD ) drug use treat type 2 diabetes . In addition reduce insulin resistance , drug favorable effect blood vessel , reduce blood vessel inflammation , potentially prevent atherosclerosis . Currently market TZDs include rosiglitazone pioglitazone . The IRIS clinical trial enroll 3936 subject approximately 170 hospital Australia , Canada , Germany , Israel , Italy , United Kingdom ( UK ) US . After initial screen blood test , participant randomly assign take either pioglitazone placebo tablet . Recruitment complete 2005-2012 , participant follow minimum 3 year .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Inclusion Criteria 1 . Ages 40 year great time randomization . 2 . Ischemic stroke TIA le 14 day 6 month randomization 3 . Documentation insulin resistance define value 3.0 Homeostasis Model Assessment insulin sensitivity ( HOMA ) . 4 . Both ability willingness provide inform consent . 5 . Presence none exclusion criterion . Exclusion Criteria Permanent Exclusions 1 . Severely disable stroke indicate inability participate schedule followup activity . 2 . Persons whose ischemic stroke TIA related structural cardiac lesion , significant head trauma , proximal arterial dissection medical instrumentation . 3 . Diabetes mellitus define recent use medication diabetes outpatient ( *see note ) two fast plasma blood sugar &gt; 126 mg/dL . 4 . HgbA1c &gt; 7.0 % . 5 . Irreversible medical condition likely affect shortterm survival ability participate study protocol . These include : Cancer chronic disease poor prognosis ( predict survival less four year ) . Severe neurologic psychiatric disease would complicate evaluation study outcome ( e.g. , dementia schizophrenia ) . 6 . History intolerance thiazolidinedione . 7 . Pregnancy desire become pregnant . 8 . Oral contraceptive use . 9 . Ongoing use oral corticosteroid . 10 . History heart failure 11 . Active liver disease define know liver disease accompanied cirrhosis , significant cholestasis , portal hypertension , hepatic encephalopathy , hepatic synthetic dysfunction , expect significant loss liver function course study . 12 . History bladder cancer . 13 . Current participation conflict clinical trial . A conflict clinical trial define trial following : Intervention known affect incidence stroke myocardial infarction . Intervention experimental drug . Outcome include stroke myocardial infarction . Exclusion participation another trial . Temporary Exclusions Persons temporary exclusion may enrol soon exclusion resolve . 1 . Alanine aminotransferase ( ALT ) &gt; 2.5 time upper limit normal . 2 . Hemoglobin &lt; 8.5 g/dl . 3 . Moderate severe pit edema foot leg ( IRIS grade 3 4 ) . 4 . Carotid surgery carotid stenting procedure schedule ( delay randomization 2 week follow procedure ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>stroke</keyword>
	<keyword>heart attack</keyword>
	<keyword>diabetes</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>insulin resistance</keyword>
</DOC>